Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...

NIH's longtime second-in-command, Larry Tabak, DDS, PhD, was forced to retire from government service. (CBS News) When Robert ...

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Patients with metastatic cancer had better quality of life, clinical outcomes, and sense of well-being when they regularly ...

The US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Adcetris ...

In her budget speech, Finance Minister Nirmala Sitharaman announced the exemption of 36 drugs used to treat cancer, rare ...

The National Pharmaceutical Pricing Authority (NPPA) has directed all drug manufacturers and marketers to reduce the Maximum ...